{
    "clinical_study": {
        "@rank": "95769", 
        "arm_group": [
            {
                "arm_group_label": "IQP-AK-102", 
                "arm_group_type": "Active Comparator", 
                "description": "2 capsules per dose, three times daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules per dose, 3 times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several\n      studies demonstrating their efficacy, we are conducting this study to look into the efficacy\n      and safety of this novel combination of glucomannan, kappa-carrageenan and xanthan gum, in\n      appetite regulation."
        }, 
        "brief_title": "Safety and Efficacy of IQP- AK-102 in Reducing Body Weight", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Weight Loss", 
            "Appetite Management"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Body Weight", 
                "Weight Loss"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 65 years\n\n          -  25\u2264BMI\u226435\n\n          -  Expressed desire for weight loss\n\n          -  Accustomed to 3 main meals/day\n\n          -  Generally in good health\n\n          -  Consistent and stable body weight 3 months prior to study enrolment\n\n          -  Consistent regular physical activity\n\n          -  Commitment to avoid the use of other weight loss products during study\n\n          -  Commitment to adhere to diet and lifestyle recommended for the study\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to the ingredients of the device (glucomannan, kappa- carrageenan\n             and xanthan gum)\n\n          -  Presence of any active gastrointestinal disease\n\n          -  Malabsorption disorders\n\n          -  Pancreatitis\n\n          -  Stenosis in the GI tract\n\n          -  Bariatric surgery\n\n          -  Any other reason deemed suitable for exclusion, per investigator's judgement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905956", 
            "org_study_id": "INQ/010013"
        }, 
        "intervention": [
            {
                "arm_group_label": "IQP-AK-102", 
                "intervention_name": "IQP-AK-102", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 6, 2013", 
        "location": {
            "contact": {
                "email": "bgrube@web.de", 
                "last_name": "Barbara Grube, MD", 
                "phone": "+49 30/892 1030"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10709"
                }, 
                "name": "Barbara Grube"
            }, 
            "investigator": {
                "last_name": "Barbara Grube, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of IQP- AK-102 in Reducing Body Weight in Overweight and Obese Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured in kg using calibrated weighing scales", 
            "measure": "Difference in the mean change in body weight between the two arms", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes from baseline to end of study", 
                "measure": "Waist and hip circumference (cm)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Changes from baseline to end of study", 
                "measure": "Body fat content and fat free mass", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Food craving questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Global evaluation of efficacy by the subjects and investigators", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Global evaluation of safety by the subjects and investigators", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}